261 related articles for article (PubMed ID: 24196579)
1. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
McGray AJ; Hallett R; Bernard D; Swift SL; Zhu Z; Teoderascu F; Vanseggelen H; Hassell JA; Hurwitz AA; Wan Y; Bramson JL
Mol Ther; 2014 Jan; 22(1):206-18. PubMed ID: 24196579
[TBL] [Abstract][Full Text] [Related]
2. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
6. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
[TBL] [Abstract][Full Text] [Related]
7. Enhanced responses to tumor immunization following total body irradiation are time-dependent.
Diab A; Jenq RR; Rizzuto GA; Cohen AD; Huggins DW; Merghoub T; Engelhorn ME; Guevara-Patiño JA; Suh D; Hubbard-Lucey VM; Kochman AA; Chen S; Zhong H; Wolchok JD; van den Brink MR; Houghton AN; Perales MA
PLoS One; 2013; 8(12):e82496. PubMed ID: 24349298
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
9. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
[TBL] [Abstract][Full Text] [Related]
10. Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.
Kleinovink JW; van Driel PB; Snoeks TJ; Prokopi N; Fransen MF; Cruz LJ; Mezzanotte L; Chan A; Löwik CW; Ossendorp F
Clin Cancer Res; 2016 Mar; 22(6):1459-68. PubMed ID: 26546617
[TBL] [Abstract][Full Text] [Related]
11. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
Granot T; Yamanashi Y; Meruelo D
Mol Ther; 2014 Jan; 22(1):112-22. PubMed ID: 24025748
[TBL] [Abstract][Full Text] [Related]
12. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
[TBL] [Abstract][Full Text] [Related]
14. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
15. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
16. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
17. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.
Bell MP; Pavelko KD
Mol Cancer Ther; 2016 Mar; 15(3):523-30. PubMed ID: 26823492
[TBL] [Abstract][Full Text] [Related]
19. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
20. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
